RxDoctor Payments Data

Edgardo Adorno-Fontanez, MD

Pulmonary Disease · San Juan, PRNPI 1063615508

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (58.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Intuitive Surgical at 58.7% of the total.

$4,285in general payments, 2019–2025

Across 22 payments — averaging $194.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Olympus Corporation Of The Americas$1K
  • Johnson & Johnson$114
  • Medtronic$72
  • Gilead$63
  • E.r. Squibb & Sons, L.L.C.$60
  • plus $49 from 1 others

What the payments were for

  • Travel & lodging$1,19428%
  • Food & beverage$59014%
  • Education$2,50058%

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical2$2,517
Olympus Corporation Of The Americas12$1,409
Johnson & Johnson2$114
Medtronic1$72
Gilead2$63
E.r. Squibb & Sons, L.L.C.1$60
Olympus Latin America, Inc.2$49

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,285 in reported general payments places this provider in the 65th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,337
Medicare patients
22
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate14$181,224
Spiriva RespimatTiotropium Bromide35$18,691
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$10,207
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,666
Wixela InhubFluticasone Propion/Salmeterol36$6,998
Fluticasone Propionate HfaFluticasone Propionate14$3,794
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$3,070
Albuterol Sulfate HfaAlbuterol Sulfate38$1,877
Fluticasone Propionate19$236
Montelukast Sodium28$188

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →